Shares of Keryx Biopharmaceuticals ,a drug developer with a focus onrenal disease, had an awful month: Shares were down nearly 40% in September.
What caused the huge downward move? See the presentation below for details.
Continue Reading Below
The article Why Keryx Biopharmaceuticals Was Obliterated in September originally appeared on Fool.com.
Brian Feroldi has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.